News & Updates

In the treatment of patients with unresectable embolization-eligible hepatocellular carcinoma (eeHCC), combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab regular interval durvalumab) regimen with or without lenvatinib substantially increases progression-free survival (PFS), as shown in the global phase 3 EMERALD-3 study.

The novel antisense oligonucleotide bepirovirsen has induced functional cure in one-fifth of patients with chronic hepatitis B virus (HBV) infection in the phase 3 B-Well 1 and B-Well 2 trials.

Individuals with chronic hepatitis D (CHD) may benefit from lonafarnib boosted with ritonavir (LNF/RTV) alone or in combination with peg-interferon-alfa (PEG), findings from the phase III D-LIVR trial have shown.

Hepatitis B virus (HBV) low-level viraemia (LLV) may increase the risk of liver-related events, as suggested in a study.

External beam radiation therapy (EBRT) after Yttrium-90 radioembolization (Y-90) does not appear to worsen hepatoxicity or inferior oncologic outcomes in patients with hepatocellular carcinoma (HCC) when compared with EBRT alone, a study has shown.

Prioritizing physical activity (PA) intensity over volume may yield greater benefits for preventing most noncommunicable diseases (NCDs), a prospective study suggests.

The Fibrosis-4 Index (FIB-4) score can be used to predict the risk of end-stage liver disease (ESLD) in young healthy adults, suggests a study.

The use of invasive intracranial pressure monitoring (IICPM) in three high-volume liver transplant centres has declined over 10 years with no associated worsening of outcomes among patients with acute liver failure (ALF), according to a study.